RCT in 73 people with schizophrenia spectrum disorders on clozapine or olanzapine with early dysglycaemia: semaglutide vs placebo lowered HbA1c at 26 weeks (mean difference -0.25%) and weight (-9.2 kg). GI adverse events were common but mild.
RCTn = 73
Sass et al. Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders: A Randomized Clinical Trial